Drug profile · INN
zolbetuximab
VYLOY
zolbetuximab (VYLOY) is a claudin-18 binding agent.
Drug details — zolbetuximab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
zolbetuximab (VYLOY) is a claudin-18 binding agent.
Key facts
Mechanism of action
Claudin-18 binding agent
Primary target: Claudin-18
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| PMDA | approved | — |
Recent coverage
FDA approves Vyloy for HER2-negative gastric and GEJ cancer
The FDA approved zolbetuximab-clzb (Vyloy) with chemotherapy for gastric and gastroesophageal junction adenocarcinoma on October 18, 2024. Astellas says it is the first and only CLDN18.2-targeted therapy approved in the U.S. for these cancers.
데일리팜 리크루트: Vyloy (zolbetuximab) Reimbursement Progress and Market Implications for Gastric Cancer
Vyloy (zolbetuximab) has passed the HIRA Pharmacoeconomic Evaluation Subcommittee and is set for Drug Reimbursement Evaluation Committee review. This analysis covers the clinical evidence, regulatory milestones, and strategic implications for pharma stakeholders.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is zolbetuximab?
zolbetuximab (VYLOY) is a claudin-18 binding agent.
What is the brand name for zolbetuximab?
VYLOY is a marketed brand name for zolbetuximab. Check FDA Drugs@FDA for the current US label holder and prescribing information.